CRDL vs. MOLN, VXRT, DBVT, SCLX, CRDF, BCAB, VIGL, OMGA, LIFE, and SGMO
Should you be buying Cardiol Therapeutics stock or one of its competitors? The main competitors of Cardiol Therapeutics include Molecular Partners (MOLN), Vaxart (VXRT), DBV Technologies (DBVT), Scilex (SCLX), Cardiff Oncology (CRDF), BioAtla (BCAB), Vigil Neuroscience (VIGL), Omega Therapeutics (OMGA), aTyr Pharma (LIFE), and Sangamo Therapeutics (SGMO). These companies are all part of the "biological products, except diagnostic" industry.
Molecular Partners (NASDAQ:MOLN) and Cardiol Therapeutics (NASDAQ:CRDL) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their dividends, earnings, valuation, community ranking, media sentiment, analyst recommendations, profitability, institutional ownership and risk.
Cardiol Therapeutics has a net margin of 0.00% compared to Cardiol Therapeutics' net margin of -885.11%. Cardiol Therapeutics' return on equity of -31.10% beat Molecular Partners' return on equity.
Cardiol Therapeutics has lower revenue, but higher earnings than Molecular Partners. Cardiol Therapeutics is trading at a lower price-to-earnings ratio than Molecular Partners, indicating that it is currently the more affordable of the two stocks.
Molecular Partners has a beta of 0.79, indicating that its stock price is 21% less volatile than the S&P 500. Comparatively, Cardiol Therapeutics has a beta of 0.87, indicating that its stock price is 13% less volatile than the S&P 500.
26.6% of Molecular Partners shares are held by institutional investors. Comparatively, 12.5% of Cardiol Therapeutics shares are held by institutional investors. 5.9% of Molecular Partners shares are held by company insiders. Comparatively, 5.3% of Cardiol Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.
Cardiol Therapeutics received 4 more outperform votes than Molecular Partners when rated by MarketBeat users. Likewise, 51.72% of users gave Cardiol Therapeutics an outperform vote while only 44.00% of users gave Molecular Partners an outperform vote.
Molecular Partners currently has a consensus target price of $4.50, indicating a potential upside of 26.76%. Cardiol Therapeutics has a consensus target price of $6.00, indicating a potential upside of 171.49%. Given Molecular Partners' stronger consensus rating and higher possible upside, analysts clearly believe Cardiol Therapeutics is more favorable than Molecular Partners.
In the previous week, Cardiol Therapeutics had 5 more articles in the media than Molecular Partners. MarketBeat recorded 7 mentions for Cardiol Therapeutics and 2 mentions for Molecular Partners. Cardiol Therapeutics' average media sentiment score of 0.93 beat Molecular Partners' score of 0.92 indicating that Molecular Partners is being referred to more favorably in the media.
Summary
Cardiol Therapeutics beats Molecular Partners on 11 of the 18 factors compared between the two stocks.
Get Cardiol Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for CRDL and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding CRDL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Cardiol Therapeutics Competitors List
Related Companies and Tools
